As the Novavax COVID-19 vaccine gained approval in the United States, it became a ray of hope for individuals who had unique vaccine side effects or autoimmune diseases. This protein-based vaccine offers an alternative to the mRNA vaccines like Pfizer and Moderna. Here’s a closer look at why some people are turning to Novavax:
1. Unique Vaccine Experiences: People with autoimmune diseases, such as autoimmune arthritis, have reported unusual side effects after receiving mRNA COVID-19 vaccines. For example, some experienced severe joint pain after an mRNA booster shot, leading to prescribed steroids to manage inflammation. While acknowledging the benefits of mRNA vaccines, these individuals sought alternative options like Novavax to minimize side effects.
2. Protein-Based Vaccine Technology: Novavax utilizes a distinct technology compared to mRNA vaccines. Instead of instructing the body to produce spike proteins from the SARS-CoV-2 virus, Novavax directly injects these proteins. These spike proteins are grown within moth cells in a laboratory, a unique approach among protein-based vaccines. Additionally, an ingredient derived from Chilean soapbark trees enhances the vaccine’s efficacy.
3. Safety and Effectiveness: Research indicates that the Novavax vaccine is on par with mRNA vaccines in terms of safety and effectiveness. However, it entered the scene later, as vaccine uptake rates dropped significantly since the initial vaccine rollout in 2021. Some experts believe that encouraging individuals who had discomfort after mRNA shots to try Novavax might help improve vaccination rates.
4. Varied Responses in Long COVID and Chronic Fatigue Syndrome: Individuals with long COVID and chronic fatigue syndrome (also known as myalgic encephalomyelitis or ME/CFS) have responded differently to COVID-19 vaccinations. Some reported improvements in fatigue, concentration, and shortness of breath following vaccination, while others experienced temporary aggravation of symptoms. Larger studies are needed to understand the vaccine’s impact fully on these conditions.
5. Challenges in Vaccine Rollout: The rollout of Novavax and mRNA vaccines has faced challenges, with pharmacies struggling to predict demand and insurance companies working on reimbursement strategies. Unlike previous vaccine offerings, these options are no longer fully covered by the federal government. As a result, an online tool was created to help people find available Novavax appointments.
In conclusion, Novavax offers an alternative for individuals with unique vaccine experiences or autoimmune conditions, but responses to vaccines vary among those with long COVID and ME/CFS. The choice between vaccines remains a personal decision, driven by individual health considerations and concerns about side effects versus the risk of COVID-19 infection.